The benefit of maintaining bipolar I patients on monotherapy with oral ZYPREXA at a dose of 5 to 20 mg/day, afterachieving a responder status for an average duration of 2 weeks, was demonstrated in a controlled trial [seeClinical Studies] . The healthcareprovider who elects to use ZYPREXA ...
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients ...
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients ...
The benefit of maintaining bipolar I patients on monotherapy with oral ZYPREXA at a dose of 5 to 20 mg/day, afterachieving a responder status for an average duration of 2 weeks, was demonstrated in a controlled trial [seeClinical Studies] . The healthcareprovider who elects to use ZYPREXA ...
The benefit of maintaining bipolar I patients on monotherapy with oral ZYPREXA at a dose of 5 to 20 mg/day, afterachieving a responder status for an average duration of 2 weeks, was demonstrated in a controlled trial [seeClinical Studies] . The healthcareprovider who elects to use ZYPREXA ...
The benefit of maintaining bipolar I patients on monotherapy with oral ZYPREXA at a dose of 5 to 20 mg/day, afterachieving a responder status for an average duration of 2 weeks, was demonstrated in a controlled trial [seeClinical Studies] . The healthcareprovider who elects to use ZYPREXA ...
The benefit of maintaining bipolar I patients on monotherapy with oral ZYPREXA at a dose of 5 to 20 mg/day, afterachieving a responder status for an average duration of 2 weeks, was demonstrated in a controlled trial [seeClinical Studies] . The healthcareprovider who elects to use ZYPREXA ...